EcoDrugPlus

Glutaminase A

Ensembl ID : ENSACIG00000015740
Gene Symbol: GLSA
1 Cross references
236 Possible Orthologues:

Glycogen Synthase Kinase 3 Alpha A

Ensembl ID : ENSACIG00000023401
Gene Symbol: GSK3AA
1 Cross references
181 Possible Orthologues:

Glycogen Synthase Kinase 3 Alpha B

Ensembl ID : ENSACIG00000014333
Gene Symbol: GSK3AB
1 Cross references
187 Possible Orthologues:

Glycogen Synthase Kinase 3 Beta, Genome Duplicate A

Ensembl ID : ENSACIG00000000702
Gene Symbol: GSK3BA
1 Cross references
208 Possible Orthologues:

Growth Hormone Secretagogue Receptor A

Ensembl ID : ENSACIG00000005906
Gene Symbol: GHSRA
1 Cross references
212 Possible Orthologues:

Guanylate Cyclase 1 Soluble Subunit Alpha 1

Ensembl ID : ENSACIG00000021450
Gene Symbol: GUCY1A1
1 Cross references
201 Possible Orthologues:

Guanylate Cyclase 1 Soluble Subunit Alpha 2

Ensembl ID : ENSACIG00000003466
Gene Symbol: GUCY1A2
2 Cross references
204 Possible Orthologues:

Guanylate Cyclase 1 Soluble Subunit Beta 1

Ensembl ID : ENSACIG00000021554
Gene Symbol: GUCY1B1
1 Cross references
211 Possible Orthologues:

Heat Shock Protein 90, Alpha (Cytosolic), Class A Member 1, Tandem Duplicate 1

Ensembl ID : ENSACIG00000002283
Gene Symbol: HSP90AA1.1
1 Cross references
305 Possible Orthologues:

Heat Shock Protein 90, Alpha (Cytosolic), Class A Member 1, Tandem Duplicate 2

Ensembl ID : ENSACIG00000002228
Gene Symbol: HSP90AA1.2
1 Cross references
317 Possible Orthologues:

Heat Shock Protein 90, Alpha (Cytosolic), Class B Member 1

Ensembl ID : ENSACIG00000014139
Gene Symbol: HSP90AB1
1 Cross references
355 Possible Orthologues:

High Mobility Group Box 1b

Ensembl ID : ENSACIG00000004633
Gene Symbol: HMGB1B
1 Cross references
512 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).